Right Ventricular FunctionBAROLONCT07632027
Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine
A study testing Prone position in people with Right Ventricular Function and Prone Position, run by Sahlgrenska University Hospital at 1 site in Sweden.
Trial summary
Right ventricular failure (RVF) is a common complication to cardiac surgery, which is associated to mortality, kidney failure, stroke, prolonged mechanical ventilation and ICU stay. The right ventricle is particularly vulnerable to an increased afterload. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Right Ventricular Function, Prone Position, Atelectasis
- What is being tested?
- Prone position
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteSweden
- Study dates
- Oct 2026to Oct 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Scheduled for cardiac surgery using cardiopulmonary bypass
Who cannot join
- BMI >40
- Emergency surgery
- Severe pulmonary disease
- Haemodynamic instability requiring Norepinephrine >0.5mcg/kg/min
- Intracardiac shunt
- Severe (or worse) tricuspid regurgitation
- Any condition which, in the judgement of the investigator, might increase the risk to the patient
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site
Cardiothoracic Intensive Care Unit
Gothenburg, 41345
Viktor Erbring, MD, +46706456664, viktor.erbring@vgregion.se
About this study
Official title: Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine (the BAROLO Study) Hemodynamic Changes Due to Prone Position in Patients After Cardiac Surgery - a Prospective Randomized Controlled Trial Evaluating the Effect of Prone Position on Right Heart Function
Right ventricular failure (RVF) is a common complication to cardiac surgery, which is associated to mortality, kidney failure, stroke, prolonged mechanical ventilation and ICU stay. The right ventricle is particularly vulnerable to an increased afterload. By increasing pulmonary vascular resistance (PVR), atelectasis might mitigate a negative effect on the right ventricle.
Recruitment maneuvers have been shown to resolve atelectasis and improve hemodynamics by increasing cardiac output and lowering PVR. However these maneuvers transiently raise airway pressures, which in turn increases right ventricular afterload, a situation often poorly tolerated by patients with RVF.
Read more
Prone position is used in patients with respiratory failure and has been shown to decrease mortality in patients with ARDS. Prone position decreases atelectasis and moves ventilation dorsally. In ARDS it also seems to mediate beneficial hemodynamic effects such as an increase in cardiac output and a decrease in PVR.
The investigators hypothesis is that prone position early after cardiac surgery will increase cardiac output by recruitment of atelectasis and thereby decrease PVR.
Read the detailed description
Recruitment and consent:
Patients will be screened for participation no later than the day before surgery. Potential participants will be given written and verbal information regarding the study and time to ask questions and consider their participation.
Randomization:
After end of surgery, at baseline in the ICU, patients will be randomly allocated (1:1 ratio) to supine position and prone position. Block randomization with variable block sizes will be performed with sequentially numbered, opaque, sealed envelopes. All performed by Statistiska konsultgruppen. Patient stratification according to cardiac index at end-surgery will be performed to ensure similar allocation of patients with cardiac index <2.2 L/min/m2 in each group. The investigator who enrolls study participants will not have access to the random allocation sequence.
Sample Size:
Based on previous studies of cardiac surgery or prone position an a priori sample size calculation was performed using a two-sample t-test comparison of means, with equally sized independent groups. With intention to detect at least a 20% difference in cardiac index in the intervention group and with 80% power, 0.05α, estimated mean CI 2.6(0.9 SD) in control group, and CI 3.2(0.9 SD) in the prone group, the estimated sample size was n=70, divided in 2 equally large groups. As patients intermittently require recurring surgery due to i.e. bleeding, patients might be excluded after inclusion. Enrolment continues until 70 participants have completed the entire study protocol.
Interim analysis:
Given uncertainty regarding expected baseline cardiac index and its standard deviation in the study population, an interim sample size reassessment will be performed after inclusion of 40% of the planned sample (n=28). The interim analysis will be limited to re-estimation of mean and standard deviation of baseline cardiac index, and will not assess treatment effects. If the observed assumptions differ substantially from those used in the original sample size calculation, the required sample size may be adjusted to preserve the planned statistical power of the study.
Description of method:
In included patients, anesthesia will be performed with Propofol, Fentanyl and Sevoflurane. As per clinical routine patients will have a central venous catheter, 1-2 arterial catheters, TEE probe and endotracheal tube inserted. Study participants will also get a pulmonary artery catheter (PAC) inserted prior to surgery to facilitate measurement of cardiac output using thermodilution and PVR. Body surface area is calculated using the Mosteller formula.
During surgery, after CPB is weaned, the attending anaesthesiologist is instructed to refrain from additional recruitment maneuvers and a PEEP >8 cmH2O. Unless FiO2 is >80% to maintain adequate oxygenation of the patient or the anaesthesiologist deems it necessary.
When surgery is finished, the patient will be moved to the Thoracic ICU. Ventilation performed with a Maquet Servo-U (Getinge, SE) is set to volume control, tidal volumes of 6 ml/kg IBW with a respiratory rate of 12-18 and PEEP 8 cmH2O. Data collection occurs in all patients in supine position (0). Hereafter the study group is turned to prone while the control group remains in supine position.
60 minutes after proning data is again collected (t1), whereafter a recruitment maneuver is performed by gradually increasing PEEP during 2,5 minutes in 6 steps to 20 cmH2O during. After 30 seconds PEEP is decreased in 6 steps during 2,5 minutes to reach PEEP 8 cmH2O. Data is collected after the recruitment maneuver (t2) and one hour after (t3), adding up to a total of 2 hours and 15 minutes in supine or prone position. The patients in prone position are turned to supine position and the last data collection occurs (t4). In total 5 time points for data collection. Postoperative care will now continue as per routine care. Patients will be extubated as soon as possible according to clinical routine and eventually discharged from the ICU.
Since a recruitment maneuver transiently increases right ventricular afterload there is a possibility not all patients will tolerate the recruitment maneuver as described above. As per clinical practice the level of airway pressures during recruitment will be adjusted when needed to avoid adverse effects.
Discontinuation of the intervention:
In order to minimize harm the following set criteria will be used to discontinue prone position:
- Hemodynamic instability with increased Norepinephrine >0.7mcg/kg/min
- Sustained arrythmia which requires treatment including DC conversion
- Any condition which, in the judgement of the investigator, might increase risk of harm to the patient
Blinding:
After allocation to supine or prone position neither the investigator, nor ordinary ICU personnel, will be blinded due to safety and impracticalities. Patients are blinded due to being under general anaesthesia during randomization until weaning from mechanical ventilation (after the study protocol is completed).
Data collection:
A site investigator will record data using a software developed by Getinge from the respirator to a designated research computer. All other data and variables, mentioned above, will be collected from the participants digital chart and real time monitoring (Philips IntelliVue \& BD Hemosphere).
Data management:
Collected data is pseudonymized and stored on a password protected designated research computer. Only authorized study personnel have access to the computer.
Original records, including signed written consent, are kept with strict confidence. These records will be kept in a secure, locked and limited access location at Sahlgrenska Univeristy Hospital during the study and after completion for an additional 10 years. At inclusion each patient is pseudonymized by receiving a participant ID, which is used in all data files.
- Conditions
- Right Ventricular Function, Prone Position, Atelectasis, Atelectases, Postoperative Pulmonary, Cardiac Output, Vasoconstriction
- Being tested
- Prone position
- Medical subject headings
- Pulmonary Atelectasis, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prone positionProcedure or surgery
Prone position is applied in the intervention group immediately after randomization, patients will be prone for a total of 2 hours and 15 minutes. During this time 3 data collection points occur (t1, t2 \& t3).
| Study group | Role | What they receive |
|---|---|---|
| Supine position | No intervention | Control group. Will remain in supine position for the whole protocol. |
| Prone position | Experimental | Will be turned to prone position after baseline data collection (0) and return to supine position before the final data collection (t4). Receives: Procedure: Prone position |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiac Index
L/min/m2
Measured: 1 hour after baseline
Secondary outcomes (16)
PVRi
Difference between and within groups
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Cardiac Index
Difference between and within groups
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
RV pressure
Looking at differences of right ventricular blood pressure between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Driving Pressure
Plateau Pressure - PEEP
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
PaO2:FiO2
Within and between groups
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Vasopressor dose
Difference of actual vasopressor dose within and between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Inotrope dose
Difference of actual inotrope dose between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
CVP
Difference in central venous pressure within and between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
PAP
Difference in pulmonary artery pressure within and between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
PCWP
Difference in pulmonary capillary wedge pressure within and between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Systemic blood pressure
Difference in systemic blood pressure within and between groups at all timepoints
Measured: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Heart rate
Difference in heart rate within and between groups at all timepoints
Measured: 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
Chest drain output
Total amount from all chest drains between Baseline and t4.
Measured: 2 hours 45 minutes after baseline
ICU length of stay
Time from start to end of the ICU visit, measured in days.
Measured: Perioperative
Time to extubation
Time from arrival to the ICU until patient's endotracheal tube is removed (extubation). Measured in hours.
Measured: Perioperative
Harms
Adverse events. Severity graded: Mild, Moderate, Severe \& Life-Threatening. Causality: Due to prone position? Other reason?
Measured: At any point in time from Baseline to 2 hours and 45 minutes after Baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study startOct 2026 (estimated)
- Primary completionMay 2029 (estimated)
- Study completionOct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Right Ventricular FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sahlgrenska University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Viktor Erbring, Sahlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07632027
- Sponsor's protocol ID
- 286380
- Acronym
- BAROLO
- Status last verified
- Oct 2026
- First submitted
- 24 Mar 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: As of now there aren't any plans to share IPD. However if good ideas for further studies on this data by other researchers appear, our plan to share IPD might change.